Welcome to our dedicated page for Biodexa Pharmaceuticals plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biodexa Pharmaceuticals plc filings document a foreign private issuer that reports current information on Form 6-K and incorporates certain disclosures into Form S-8 and Form F-3 registration statements. The records cover preliminary annual results; pipeline disclosures for eRapa, MTX240 and tolimidone; clinical trial authorizations and enrollment updates; and material agreements such as the MTX240 license and collaboration arrangement.
Capital-structure disclosures describe ADS units, pre-funded warrants, Series L warrants, public-offering documents, ADR ratio matters and the relationship between ADSs and ordinary shares. Governance and corporate filings also cover executive and board appointments, exhibit-based press releases, and other foreign-issuer current reports tied to Biodexa’s biopharmaceutical development programs.
Biodexa Pharmaceuticals Plc filed an amendment to a Schedule 13G/A reporting that Armistice Capital, LLC and Steven Boyd jointly beneficially own 187,975 American Depositary Shares, representing 9.99% of the class. Each ADS represents four hundred ordinary shares. The filing states Armistice Capital exercises shared voting and dispositive power over the reported shares on behalf of its client, Armistice Capital Master Fund Ltd., and that the Master Fund "disclaims beneficial ownership" of the shares by virtue of its Investment Management Agreement. The filing is signed by Steven Boyd on 05/15/2026.
Biodexa Pharmaceuticals PLC has called its Annual General Meeting for 17 June 2026 and is asking shareholders to approve a major share capital reorganisation. On 6 May 2026 the company had 373,056,808,922 existing ordinary shares, equal to about 746,113 ADSs at a 500,000:1 ratio.
The Board proposes consolidating every 10,000 existing ordinary shares into one £0.01 consolidated share, then subdividing each into one new ordinary share of £0.000001 and 9,999 E deferred shares with negligible rights. The ADS ratio would change to 50 ordinary shares per ADS so the number of ADSs remains about 746,113.
Shareholders are also being asked to grant authority to allot new shares up to £25,000,000 nominal and to disapply pre-emption rights on the same amount until the 2029 AGM, and to adopt new articles of association to accommodate the new E deferred shares.
Biodexa Pharmaceuticals PLC is registering the issuance of up to 489,000 American Depositary Shares (each ADS = 100,000 Ordinary Shares) representing 48,900,000,000 Ordinary Shares issuable upon exercise of Pre-Funded Warrants, plus up to 6,097,562 ADS representing 609,756,200,000 Ordinary Shares issuable upon exercise of Series L Warrants, and up to 152,439 ADS representing 15,243,900,000 Ordinary Shares issuable upon exercise of Placement Agent Warrants.
The prospectus describes exercise prices (Pre-Funded Warrants at $0.0001 per Depositary Share; Series L and Placement Agent Warrants at $3.28 per Depositary Share), cash‑or‑cashless exercise mechanics, beneficial ownership limits (commonly 9.99% or 4.99%) and plan of distribution terms. It also states 324,156,808,922 Ordinary Shares outstanding as of March 12, 2026 and a pro forma total of 998,056,908,922 Ordinary Shares assuming full exercise of the referenced warrants.
Biodexa Pharmaceuticals PLC registered for resale an aggregate of 943,400,000 Ordinary Shares represented by 9,434 Depositary Shares, issuable upon exercise of Series G warrants. The prospectus states the company will not receive any proceeds from resale by the selling shareholders; net proceeds will go to those selling shareholders, although the company would receive proceeds if warrants are exercised for cash. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 12, 2026.
Biodexa Pharmaceuticals PLC registers for resale 1,701,800,000 Ordinary Shares represented by 17,018 Depositary Shares, each Depositary Share representing 100,000 Ordinary Shares, for sale from time to time by identified selling shareholders.
The prospectus states the Company will receive no proceeds from resale by the selling shareholders, although the Company may receive proceeds if Series J warrants are exercised for cash; if all Series J warrants were exercised for cash in full, proceeds would be approximately $4.3 million. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 1, 2026.
Biodexa Pharmaceuticals PLC registers for resale 171,700,000 Ordinary Shares represented by 1,717 Depositary Shares, issuable upon exercise of pre-funded warrants from a December 2023 private placement. The prospectus states the Company will receive proceeds only if warrants are exercised for cash at an exercise price of $0.025 per share; otherwise all net proceeds will go to the selling shareholders. The Depositary Shares trade on NASDAQ under the symbol BDRX and each Depositary Share represents 100,000 Ordinary Shares. The prospectus discloses 324,156,808,922 Ordinary Shares outstanding as of March 12, 2026 and notes potential sales may occur in market, negotiated or brokered transactions.
Biodexa Pharmaceuticals PLC registers for resale up to 299,261,540,000 Ordinary Shares represented by 2,992,615 Depositary Shares (ADS) held or issuable to C/M Capital Master Fund, LP under an equity line Purchase Agreement.
The shares are being registered for resale by the Selling Shareholder; Biodexa is not selling shares here and will not receive proceeds from resale, although Biodexa may receive up to $35.0 million in aggregate gross proceeds if it elects to sell Depositary Shares to the Selling Shareholder under the Purchase Agreement. Each Depositary Share represents 100,000 Ordinary Shares. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 12, 2026.
Biodexa Pharmaceuticals PLC files a resale prospectus registering an aggregate of 109,800,000 Ordinary Shares, represented by 1,098 Depositary Shares, issuable upon exercise of Series D Warrants.
The prospectus states we will not receive proceeds from sales by the selling shareholders; proceeds will go to those sellers, though the company may receive proceeds if warrants are exercised for cash. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 12, 2026.